Inhibition of Cellular Esterases by the Antitumour Imidazotetrazines Mitozolomide and Temozolomide: Demonstration by Flow Cytometry and Conventional Spectrofluorimetry

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1989 Jan 1

PMID 2557170

Citations 1

Authors

C Dive

P Workman

J.V. Watson

Affiliations

Soon will be listed here.

Abstract

Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were largely inactive. We now report results obtained with the developmental imidazotetrazines mitozolomide and temozolomide in comparison with BCNU, the novel alkylating agents clomesome and cyclodisone, and the active mitozolomide metabonate MCTIC. Inhibition of EMT6 mouse mammary-tumour esterases was seen for mitozolomide and temozolomide, and activity against purified porcine carboxylesterase was demonstrated. Flow cytometric analysis showed that inhibition occurred across the entire EMT6 cell population, with no evidence of a subpopulation resistant to enzyme inhibition. Inhibitory potency for the imidazotetrazines was much weaker than for BCNU. With EMT6 cells, I50 values from flow cytometry were 9.7 x 10(-3) M and 1.5 x 10(-3) M for mitozolomide and temozolomide compared with 3.7 x 10(-4) M for BCNU. These were higher than the ID50 values for in vitro antitumour activity (MTT assay), 8.5 x 10(-6) M in the case of mitozolomide and 1.2 x 10(-5) M for BCNU, but similar to that of 5.6 x 10(-4) M for the less toxic temozolomide. MCTIC and cyclodisone showed very low activity, but significant inhibition was seen for clomesome. The results are consistent with the view that the imidazotetrazines do not exhibit major carbamoylating ability, although significant effects are seen at cytotoxic concentrations of temozolomide. In addition, the potential for the generation of carbamoylating species at the enzyme active site cannot be ruled out.

Citing Articles

Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.

Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm E Mol Cancer Ther. 2008; 7(12):3842-51.

PMID: 19056673 PMC: 2653264. DOI: 10.1158/1535-7163.MCT-08-0516.

References

Morten J, Margison G . Increased O6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis. 1988; 9(1):45-9. DOI: 10.1093/carcin/9.1.45. View

Brennand J, Margison G . Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci U S A. 1986; 83(17):6292-6. PMC: 386489. DOI: 10.1073/pnas.83.17.6292. View

Hartley J, Gibson N, Kohn K, Mattes W . DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer Res. 1986; 46(4 Pt 2):1943-7. View

Gibson N, Erickson L, Kohn K . DNA damage and differential cytotoxicity produced in human cells by 2-chloroethyl (methylsulfonyl)methanesulfonate (NSC 338947), a new DNA-chloroethylating agent. Cancer Res. 1985; 45(4):1674-9. View

Gibson N, Hartley J, Kohn K . DNA reactivity and in vitro cytotoxicity of the novel antitumor agent 1,5,2,4-dioxadithiepane-2,2,4,4-tetraoxide (NSC-348948) in human embryo cells. Cancer Res. 1986; 46(4 Pt 1):1679-83. View

Gibson N, Hartley J, Strong J, Kohn K . 2-Chloroethyl (methylsulfonyl)methanesulfonate (NSC-338947), a more selective DNA alkylating agent than the chloroethylnitrosoureas. Cancer Res. 1986; 46(2):553-7. View

Dive C, Workman P, Watson J . Improved methodology for intracellular enzyme reaction and inhibition kinetics by flow cytometry. Cytometry. 1987; 8(6):552-61. DOI: 10.1002/cyto.990080604. View

Rockwell S, Kallman R, Fajardo L . Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972; 49(3):735-49. View

Gibson N, Hartley J, La France R, Vaughan K . Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles. Carcinogenesis. 1986; 7(2):259-65. DOI: 10.1093/carcin/7.2.259. View

10.

Gibson N, Hickman J, Erickson L . DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 1984; 44(5):1772-5. View

11.

Twentyman P, LUSCOMBE M . A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987; 56(3):279-85. PMC: 2002206. DOI: 10.1038/bjc.1987.190. View

12.

Hickman J, Stevens M, Gibson N, Langdon S, Fizames C, Lavelle F . Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res. 1985; 45(7):3008-13. View

13.

Watson J . Enzyme kinetic studies in cell populations using fluorogenic substrates and flow cytometric techniques. Cytometry. 1980; 1(2):143-51. DOI: 10.1002/cyto.990010209. View

14.

Stevens M, Hickman J, Langdon S, Chubb D, Vickers L, Stone R . Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987; 47(22):5846-52. View

15.

Mulcahy R . Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer-) cell lines. Cancer Res. 1986; 46(6):2892-7. View

16.

Horgan C, Tisdale M . Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451). Biochem Pharmacol. 1984; 33(14):2185-92. DOI: 10.1016/0006-2952(84)90652-x. View

17.

Watson J, Chambers S, Workman P, Hornsnell T . A flow cytofluorimetric method for measuring enzyme reaction kinetics in intact cells. FEBS Lett. 1977; 81(1):179-82. DOI: 10.1016/0014-5793(77)80954-x. View

18.

Lindahl T . The 1987 Walter Hubert lecture. Regulation and deficiencies in DNA repair. Br J Cancer. 1987; 56(2):91-5. PMC: 2002141. DOI: 10.1038/bjc.1987.163. View

19.

Gibson N, Mattes W, Hartley J . Identification of specific DNA lesions induced by three classes of chloroethylating agents: chloroethylnitrosoureas, chloroethylmethanesulfonates and chloroethylimidazotetrazines. Pharmacol Ther. 1985; 31(1-2):153-63. DOI: 10.1016/0163-7258(85)90042-7. View

20.

Dive C, Workman P, Watson J . Inhibition of intracellular esterases by antitumour chloroethylnitrosoureas. Measurement by flow cytometry and correlation with molecular carbamoylation activity. Biochem Pharmacol. 1988; 37(20):3987-93. DOI: 10.1016/0006-2952(88)90084-6. View